Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostaglandin E1 versus linsidomine chlorhydrate in erectile dysfunction

H E Wegner1, H H Knispel, R Klän

  • 1Department of Urology, Universitätsklinikum Steglitz, Freie Universität Berlin, Germany.

Urologia Internationalis
|January 1, 1994
PubMed
Summary

Linsidomine chlorhydrate (SIN-1) is not an effective treatment for erectile dysfunction. Prostaglandin E1 (PGE1) demonstrated superior results in clinical trials, with SIN-1 showing poorer performance and no significant side effect differences.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rupture of the Left Renal Fornix after Vaginal Repair of Postpartum Vesicovaginal Fistula.

Geburtshilfe und Frauenheilkunde·2014
Same author

Results of a BoNT/A antibody study in children and adolescents after onabotulinumtoxin A (Botox®) detrusor injection.

Urologia internationalis·2011
Same author

[How come? What for? Why? Questions on the topic of "Botulinum toxin in urology"].

Der Urologe. Ausg. A·2007
Same author

[A look beyond urology: vaginal cancer].

Der Urologe. Ausg. A·2006
Same author

Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis.

Neurourology and urodynamics·2006
Same author

A new option for the management of urethral trauma: primary reconstruction of posterior urethral disruption with a buccal mucosa transplant.

International urology and nephrology·2005

Area of Science:

  • Urology
  • Pharmacology
  • Neuroscience

Background:

  • Nitric oxide (NO) is identified as the primary neurotransmitter for cavernous smooth muscle relaxation.
  • Previous research on linsidomine chlorhydrate (SIN-1) for erectile dysfunction has yielded inconsistent outcomes.
  • Understanding NO's role is crucial for developing effective erectile dysfunction therapies.

Purpose of the Study:

  • To evaluate the efficacy of SIN-1 as a treatment for erectile dysfunction.
  • To compare the effectiveness of SIN-1 against prostaglandin E1 (PGE1).
  • To determine optimal dosages for SIN-1 in managing erectile dysfunction.

Main Methods:

  • A single-blind, cross-over trial involving 20 patients with erectile dysfunction.
  • Comparison of SIN-1 (at 1 mg and 2 mg) with PGE1.

Related Experiment Videos

  • Assessment of treatment response and side effects.

    • Main Results:

    • Prostaglandin E1 (PGE1) consistently produced superior treatment outcomes.
    • Linsidomine chlorhydrate (SIN-1) demonstrated statistically significant poorer performance compared to PGE1.
    • No significant differences in side effect profiles were observed between the treatments.

    Conclusions:

    • Linsidomine chlorhydrate (SIN-1) is not a viable alternative to PGE1 for treating erectile dysfunction.
    • Further research may be needed to explore other NO-related therapies.
    • PGE1 remains a more effective option for managing erectile dysfunction in this patient cohort.